Second, we need new kinds of partnerships between academia and government and the private sector and patient organizations, just like the one I've been describing here, in terms of the way in which we could go after repurposing new compounds.
其次，我们需要新型的合作关系 在学术界，政府，私有部门 以及病人组织间，跟我刚才提到的一样 然后利用这种关系进行药物再定位